Factors predicting adverse short-term outcomes in patients with acute cholangitis undergoing ERCP: A single center experience

Table 4 Univariate analysis for length of stay of greater than 10 d (90^th percentile)

Variable	OR (95%CI)	P value
Age	1.05 (0.92-1.19)	0.47
Male	0.98 (0.42-2.31)	0.97
Body mass index	1.07 (0.71-1.60)	0.74
Smoking	1.13 (0.37-3.41)	0.83
Primary sclerosing cholangitis	0.60 (0.21-1.71)	0.34
Systemic inflammatory response syndrome	2.02 (0.75-5.40)	0.16
Charlson comorbidity index	1.04 (0.85-1.28)	0.69
American Society of Anesthesiology physical classification > 3	3.12 (1.47-6.63)	0.003
Altered mental status	2.03 (0.39-10.67)	0.33
Statins at admission	0.90 (0.28-2.88)	1
Anti-platelets meds at admission	1.03 (0.35-3.01)	1
Door to ERCP time
≤ 24 h (reference)	-	-
24-48 h	2.66 (1.12-6.34)	0.03
48-72 h	2.82 (1.17-6.82)	0.02
> 72 h	3.57 (1.39-9.17)	0.03
Pre-ERCP bilirubin	1.07 (0.99-1.15)	0.08
Positive blood cultures	1.70 (0.69-4.21)	0.25
Presence of fever	1.04 (0.43-2.53)	0.94
Post-ERCP pancreatitis	3.00 (0.26-34.39)	0.38
Serum creatinine at admission	1.48 (1.13-1.94)	0.004
Presence of persistent cardiovascular failure	3.18 (1.15-8.79)	0.04
Presence of persistent respiratory failure	13.81 (2.38-80.11)	0.004
Presence of persistent renal failure	4.81 (1.74-13.29)	0.004
Transfer patients	0.93 (0.39-2.25)	0.87

ERCP: Endoscopic retrograde cholangiopancreatography.